Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | CTSG | P08311 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032267 | 1.00 | LMNA (0.51) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL14370539 | 1.00 | LMNA (0.51) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL8563008 | 0.81 | CTSK (0.46) | — | |
| SCHEMBL4185708 | 0.81 | LMNA (0.50) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL13621588 | 0.80 | LMNA (0.59) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL13048136 | 0.80 | LMNA (0.59) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL5089400 | 0.78 | LMNA (0.50) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL14574458 | 0.78 | LMNA (0.56) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL14420891 | 0.77 | LMNA (0.59) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL13426750 | 0.77 | LMNA (0.59) | LMNAHPGDALDH1A1HDAC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432383-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE-SERIPHARM (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7279586-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 2007-10-09 | — | — | US | disclosed |
| US-20070208185-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | CHANTELOUP LUC | 2007-09-06 | — | — | US | disclosed |
| US-7220871-B2 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20050222089-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | CHANTELOUP LUC | 2005-10-06 | — | — | US | disclosed |
| US-6825365-B2 | FORMED AS ENANTIOMERS OF CIS-BETA-PHENYLGLYCIDIC ACID/BETA-PHENYLISOSERINE REACT WITH NITRILE COMPOUND VIA RITTER REACTION | NOVASEP (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20040220256-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | CHANTELOUP LUC (FR) | 2004-11-04 | — | — | US | disclosed |
| US-20020068833-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM | 2002-06-06 | — | — | US | disclosed |
| EP-0863887-B1 | INTERMEDIARY COMPOUNDS FOR THE HEMISYNTHESIS OF TAXANES AND PREPARATION PROCESSES THEREFOR | SERIPHARM (FR) | 2002-01-23 | — | — | EP | disclosed |
| US-6265587-B1 | REACTING ARYLGLYCIDATE WITH A NITRILE TO OBTAIN B-ARYLISOSERINE DERIVATIVE AND TREATING PRODUCT WITH LEWIS ACID TO OBTAIN OXAZOLINE COMPOUND | SOCIETE D'ETUDE ET DE RECHERCHE EN INGENIERIE PHARMACEUTIQUE SERIPHARM (FR) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068833-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | DHPS, DOHH, HADH | LMNA 1897/4885HPGD 275/4885ALDH1A1 561/4885 |
| US-20070208185-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | DHPS, HASPIN, BDNF | LMNA 708/4885HPGD 371/4885ALDH1A1 718/4885 |
| US-20050222089-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | DHPS, HASPIN, BDNF | LMNA 708/4885HPGD 371/4885ALDH1A1 718/4885 |
| US-20040220256-A1 | Intermediates for the hemisynthesis of taxanes and preparation processes therefor | DHPS, HASPIN, BDNF | LMNA 708/4885HPGD 371/4885ALDH1A1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.